An Overview of the Fovista and Rinucumab Trials and the Fate of Anti-PDGF Medications

The vitreoretinal community will remember 2016 as the year that unfavorable anti-platelet-derived growth factor (anti-PDGF) clinical trial results ended the development of Fovista (pegpleranib; Ophthotech, New York, NY) and Rinucumab (Regeneron, Tarrytown, NY). The failure of these trials reaffirmed...

Full description

Saved in:
Bibliographic Details
Published inOphthalmic surgery, lasers & imaging Vol. 48; no. 2; pp. 100 - 104
Main Authors Dunn, Evan N, Hariprasad, Seenu M, Sheth, Veeral S
Format Journal Article
LanguageEnglish
Published United States SLACK INCORPORATED 01.02.2017
Subjects
Angiogenesis Inhibitors - administration & dosage
Clinical outcomes
Clinical trials
Clinical Trials as Topic - methods
Drugs, Investigational
Eye diseases
Humans
Intravitreal Injections
Macular Degeneration - drug therapy
Platelet-Derived Growth Factor - antagonists & inhibitors
Prescription drugs
Online AccessGet full text

Cover

More Information
Summary:The vitreoretinal community will remember 2016 as the year that unfavorable anti-platelet-derived growth factor (anti-PDGF) clinical trial results ended the development of Fovista (pegpleranib; Ophthotech, New York, NY) and Rinucumab (Regeneron, Tarrytown, NY). The failure of these trials reaffirmed how important the innovations made in 2006 with anti-vascular endothelial growth factor (anti-VEGF) were to our field and our patients.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:2325-8160
2325-8179
DOI:10.3928/23258160-20170130-02